Shrinking Bat DNA and Elastic Genomes – Quanta Magazine

Parsing the creatures 2 billion base pairs, Feschotte and his colleagues did stumble on something strange. We found some very weird transposons, he said. Because these oddball parasite sequences didnt appear in other mammals, they were likely to have invaded after bats diverged from other lineages, perhaps picked up from an insect snack some 30 to 40 million years ago. Whats more, they were incredibly active. Probably 20 percent or more of the bats genome is derived from this fairly recent wave of transposons, Feschotte said. It raised a paradox because when we see an explosion of transposon activity, wed predict an increase in size. Instead, the bat genome had shrunk. So we were puzzled.

There was only one likely explanation: Bats must have jettisoned a lot of DNA. When Kapusta joined Feschottes lab in 2011, her first project was to find out how much. By comparing transposons in bats and nine other mammals, she could see which pieces many lineages shared. These, she determined, must have come from a common ancestor. Its really like looking at fossils, she said. Researchers had previously assembled a rough reconstruction of the ancient mammalian genome as it might have existed 100 million years ago. At 2.8 billion base pairs, it was nearly human-size.

Next, Kapusta calculated how much ancestral DNA each lineage had lost and how much new material it had gained. As she and Feschotte suspected, the bat lineages had churned through base pairs, dumping more than 1 billion while accruing only another few hundred million. Yet it was the other mammals that made their jaws drop.

Mammals are not especially diverse when it comes to genome size. In many animal groups, such as insects and amphibians, genomes vary more than a hundredfold. By contrast, the largest genome in mammals (in the red viscacha rat) is only five times as big as the smallest (in the bent-wing bat). Many researchers took this to mean that mammalian genomes just dont have much going on. As Susumu Ohno, the noted geneticist and expert in molecular evolution, put it in 1969: In this respect, evolution of mammals is not very interesting.

But Kapustas data revealed that mammalian genomes are far from monotonous, having reaped and purged vast quantities of DNA. Take the mouse. Its genome is roughly the same size it was 100 million years ago. And yet very little of the original remains. This was a big surprise: In the end, only one-third of the mouse genome is the same, said Kapusta, who is now a research associate in human genetics at the University of Utah and at the USTAR Center for Genetic Discovery. Applying the same analysis to 24 bird species, whose genomes are even less varied than those of mammals, she showed that they too have a lively genetic history.

No one predicted this, said J. Spencer Johnston, a professor of entomology at Texas A&M University. Even those genomes that didnt change size over a huge period of time they didnt just sit there. Somehow they decided what size they wanted to be, and despite mobile elements trying to bloat them, they didnt bloat. So then the next obvious question is: Why the heck not?

Feschottes best guess points at transposons themselves. They provide a very natural mechanism by which gain provides the template to facilitate loss, he said. Heres how: As transposons multiply, they create long strings of nearly identical code. Parts of the genome become like a book that repeats the same few words. If you rip out a page, you might glue it back in the wrong place because everything looks pretty much the same. You might even decide the book reads just fine as is and toss the page in the trash. This happens with DNA too. When its broken and rejoined, as routinely happens when DNA is damaged but also during the recombination of genes in sexual reproduction, large numbers of transposons make it easy for strands to misalign, and that slippage can result in deletions. The whole array can collapse at once, Feschotte said.

This hypothesis hasnt been tested in animals, but there is evidence from other organisms. Its not so different from what were seeing in plants with small genomes, Leitch said. DNA in these species is often dominated by just one or two types of transposons that amplify and then get eliminated. The turnover is very dynamic: in 3 to 5 million years, half of any new repeats will be gone.

Thats not the case for larger genomes. What we see in big plant genomes and also in salamanders and lungfish is a much more heterogeneous set of repeats, none of which are present in [large numbers], Leitch said. She thinks these genomes must have replaced the ability to knock out transposons with a novel and effective way of silencing them. What they do is, they stick labels onto the DNA that signal to it to become very tightly condensed sort of squished so it cant be read easily. That alteration stops the repeats from copying themselves, but it also breaks the mechanism for eliminating them. So over time, Leitch explained, any new repeats get stuck and then slowly diverge through normal mutation to produce a genome full of ancient degenerative repeats.

Meanwhile, other forces may be at play. Large genomes, for instance, can be costly. Theyre energetically expensive, like running a big house, Leitch said. They also take up more space, which requires a bigger nucleus, which requires a bigger cell, which can slow processes like metabolism and growth. Its possible that in some populations, under some conditions, natural selection may constrain genome size. For example, female bow-winged grasshoppers, for mysterious reasons, prefer the songs of males with small genomes. Maize plants growing at higher latitudes likewise self-select for smaller genomes, seemingly so they can generate seed before winter sets in.

Some experts speculate that a similar process is going on in birds and bats, which may need small genomes to maintain the high metabolisms needed for flight. But proof is lacking. Did small genomes really give birds an advantage in taking to the skies? Or had the genomes of birds flightless dinosaur ancestors already begun to contract for some other reason, and did the physiological demands of flight then shrink the genomes of modern birds even more? We cant say whats cause and effect, Suh said.

Its also possible that genome size is largely a result of chance. My feeling is theres one underlying mechanism that drives all this variability, said Mike Lynch, a biologist at Indiana University. And thats random genetic drift. Its a principle of population genetics that drift whereby a genetic variant becomes more or less common just by sheer luck is stronger in small groups, where theres less variation. So when populations decline, such as when new species diverge, the odds increase that lineages will drift toward larger genomes, even if organisms become slightly less fit. As populations grow, selection is more likely to quash this trait, causing genomes to slim.

None of these models, however, fully explain the great diversity of genome forms. The way I think of it, youve got a bunch of different forces on different levels pushing in different directions, Gregory said. Untangling them will require new kinds of experiments, which may soon be within reach. Were just at the cusp of being able to write genomes, said Chris Organ, an evolutionary biologist at Montana State University. Well be able to actually manipulate genome size in the lab and study its effects. Those results may help to disentangle the features of genomes that are purely products of chance from those with functional significance.

Many experts would also like to see more analyses like Kapustas. (Lets do the same thing in insects! Johnston said.) As more genomes come online, researchers can begin to compare larger numbers of lineages. Four to five years from now, every mammal will be sequenced, Lynch said, and well be able to see whats happening on a finer scale. Do genomes undergo rapid expansion followed by prolonged contraction as populations spread, as Lynch suspects? Or do changes happen smoothly, untouched by population dynamics, as Petrovs and Feschottes models predict and recent work in flies supports?

Or perhaps genomes are unpredictable in the same way life is unpredictable with exceptions to every rule. Biological systems are like Rube Goldberg machines, said Jeff Bennetzen, a plant geneticist at the University of Georgia. If something works, it will be done, but it can be done in the most absurd, complicated, multistep way. This creates novelty. It also creates the potential for that novelty to change in a million different ways.

Go here to see the original:

Shrinking Bat DNA and Elastic Genomes - Quanta Magazine

Genome Sequencing Shows Spiders, Scorpions Share Ancestor – Laboratory Equipment

In collaboration with scientists from the U.K., Europe, Japan and the United States, researchers at the Human Genome Sequencing Center at Baylor College of Medicine have discovered a whole genome duplication during the evolution of spiders and scorpions. The study appears in BMC Biology.

Researchers have long been studying spiders and scorpions for both applied reasons, such as studying venom components for pharmaceuticals and silks for materials science, and for basic questions such as the reasons for the evolution and to understand the development and ecological success of this diverse group of carnivorous organisms.

As part of a pilot project for the i5K, a project to study the genomes of 5,000 arthropod species, the Human Genome Sequencing Center analyzed the genome of the house spider Parasteatoda tepidariorum a model species studied in laboratories and the Arizona bark scorpion Centruroides sculpturatus, the most venomous scorpion in North America.

Analysis of these genomes revealed that spiders and scorpions evolved from a shared ancestor more than 400 million years ago, which made new copies of all of the genes in its genome, a process called whole genome duplication. Such an event is one of the largest evolutionary changes that can happen to a genome and is relatively rare during animal evolution.

It is tremendously exciting to see rapid progress in our molecular understanding of a species that we coexist with on planet earth. Spider genome analysis is particularly tricky, and we believe this is one of the highest quality spider genomes to date, said Stephen Richards, associate professor in the Human Genome Sequencing Center, who led the genome sequencing at Baylor.

Similarly, there also have been two whole genome duplications at the origin of vertebrates, fuelling long-standing debate as to whether the duplicated genes enabled new biological complexity in the evolution of the vertebrate lineage leading to mammals. The new finding of a whole genome duplication in spiders and scorpions therefore provides a valuable comparison to the events in vertebrates and could help reveal genes and processes that have been important to our own evolution.

While most of the new genetic material generated by whole genome duplication is subsequently lost, some of the new gene copies can evolve new functions and may contribute to the diversification of shape, size, physiology and behavior of animals, said Alistair McGregor, professor of evolutionary developmental biology at Oxford Brookes University and lead author of the research. Comparing the whole genome duplication in spiders and scorpions with the independent events in vertebrates reveals a striking similarity. In both cases, duplicated clusters of Hox genes have been retained. These are very important genes that regulate development of body structures in all animals, and therefore can cause evolutionary changes in animal body plans.

The study also found that the copies of spider Hox genes show differences in when and where they are expressed, suggesting they have evolved new functions.

McGregor explains that these changes may help clarify the evolutionary innovations in spiders and scorpions including specialized limbs and how they breathe, as well as the production of different types of venom and silk, which spiders use to capture and kill their prey.

Many people fear spiders and scorpions, but this research shows what a beautiful part of the evolutionary tree they represent, said Richard Gibbs, director of the Human Genome Sequencing Center and the Wofford Cain Chair and professor of molecular and human genetics at Baylor.

Costs have now dropped rapidly enough from tens of millions of dollars to merely a few thousand dollars for this genomic analyses to now be performed on any species, Richards said. There is still so much more to learn about the life on earth around us, and I believe this result is just the beginning of understanding the molecular make up of spiders.

See the original post:

Genome Sequencing Shows Spiders, Scorpions Share Ancestor - Laboratory Equipment

Marc Malandro of Pitt’s Innovation Institute leaving for Chan Zuckerberg Initiative – Pittsburgh Post-Gazette


Pittsburgh Post-Gazette
Marc Malandro of Pitt's Innovation Institute leaving for Chan Zuckerberg Initiative
Pittsburgh Post-Gazette
Evan Facher has been named interim director of the Innovation Institute effective Aug. 19. Mr. Facher, who has a doctorate degree in human genetics from Pitt and an MBA from Case Western Reserve University, joined the Innovation Institute as director ...

and more »

See the rest here:

Marc Malandro of Pitt's Innovation Institute leaving for Chan Zuckerberg Initiative - Pittsburgh Post-Gazette

Scientists Claim to Disprove Biblical Account of Canaanites – The Jewish Press – JewishPress.com (blog)

Photo Credit: Youtube

{Originally posted to the Elder of Ziyon website}

A new DNA study has just been released that says that ancient Canaanites were not annihilated by the Children of Israel, but are the ancestors of todays Lebanese.

A new genetic study from the Wellcome Trust Sanger Institute has found that far from being destroyed, the Canaanites morphed into the inhabitants of modern Lebanon.

Scientists in the United Kingdom-based genetic research center sequenced the genomes of five 4,000-year-old Canaanite individuals and compared them to other ancient and present-day populations, including a sample of 99 modern Lebanese.

The results, published July 27 in the American Journal of Human Genetics, show that 93 percent of the ancestry of modern Lebanese ancestry comes from the Canaanites.

Had they been destroyed by the Israelites, though, it would have been a form of patricide.

The study took the DNA of human remains in Sidon and compared it to those of modern Lebanese:

Uncertainties also surround the fate of the Canaanites: the Bible reports the destruction of the Canaanite cities and the annihilation of its people; if true, the Canaanites could not have directly contributed genetically to present-day populations. However, no archaeological evidence has so far been found to support widespread destruction of Canaanite cities between the Bronze and Iron Ages: cities on the Levant coast such as Sidon and Tyre show continuity of occupation until the present day.

We sampled the petrous portion of temporal bones belonging to five ancient individuals dated to between 3,750 and 3,650 years ago (ya) from Sidon, which was a major Canaanite city-state during this period.

Only one problem: the Children of Israel never conquered Sidon, or many other Canaanite cities, nor did they destroy the Canaanites according to the Bible.

God indeed commanded the destruction of the Canaanites (Deuteronomy 20:17) but the beginning of Judges shows that it never happened (NIV translation, easier to understand than JPS)

27 But Manasseh did not drive out the people of Beth Shan or Taanach or Dor or Ibleam or Megiddo and their surrounding settlements, for the Canaanites were determined to live in that land. 28 When Israel became strong, they pressed the Canaanites into forced labor but never drove them out completely. 29 Nor did Ephraim drive out the Canaanites living in Gezer, but the Canaanites continued to live there among them. 30 Neither did Zebulun drive out the Canaanites living in Kitron or Nahalol, so these Canaanites lived among them, but Zebulun did subject them to forced labor. 31 Nor did Asher drive out those living in Akko or Sidon or Ahlab or Akzib or Helbah or Aphek or Rehob. 32 The Asherites lived among the Canaanite inhabitants of the land because they did not drive them out. 33 Neither did Naphtali drive out those living in Beth Shemesh or Beth Anath; but the Naphtalites too lived among the Canaanite inhabitants of the land, and those living in Beth Shemesh and Beth Anath became forced laborers for them. 34 The Amorites confined the Danites to the hill country, not allowing them to come down into the plain. 35 And the Amorites were determined also to hold out in Mount Heres, Aijalon and Shaalbim, but when the power of the tribes of Joseph increased, they too were pressed into forced labor.

Indeed, David bought cedar trees from Sidon and Tyre to build the Temple.Queen Jezebel was the daughter of the king of Sidon and swayed her husband Ahab into worshiping false gods.

All the study proved is that Sidon was never destroyed and todays Lebanese descended from ancient Phoenicians, which everyone pretty much knew already.

The DNA tests actually prove the Biblical account that the Israelites never conquered Sidon. These scientists had an agenda beyond science.

Original post:

Scientists Claim to Disprove Biblical Account of Canaanites - The Jewish Press - JewishPress.com (blog)

Senator announces bipartisan health care hearing on Obamacare – CNN

Sen. Lamar Alexander, R-Tennessee, said the Senate health committee will hold bipartisan health care hearings on how to repair the individual market. In the House, a group of 40 lawmakers from both parties endorsed an outline of ideas aimed at making urgent fixes to Obamacare.

The step toward bipartisanship on health care comes as some Republicans consider an approach that diverges from the president's stance.

In tweets this weekend, he threatened to stop paying insurance companies cost-sharing subsidies that help lower out-of-pocket expenses for low-income policyholders, calling them "bailouts."

Here are some of the bipartisan efforts underway in Congress over Obamacare.

"If your house is on fire, you want to put out the fire, and the fire in this case is the individual health insurance market," he said in a statement. "Both Republicans and Democrats agree on this."

Alexander said in the statement that he was working with Sen. Patty Murray, D-Washington, to make the hearings bipartisan.

Congress has to come up with a solution before September 27, when insurers sign contracts with the federal government over what insurance plans to sell on the exchange for 2018. About 18 million Americans who get their insurance in the individual market stand to be affected, he said.

"Unless we act, many of them may not have policies available to buy in 2018 because insurance companies will pull out of collapsing markets," Alexander said.

The senator also urged Trump to temporarily keep making the cost-sharing payments so Congress could work on stabilizing the individual market for 2018.

Last week, Alexander voted for two out of the three repeal Obamacare bills that went up for a vote in the Senate.

In the House, a group of around 40 Republicans and Democrats known as the Problem Solvers Caucus endorsed an outline of ideas aimed at making urgent fixes to Obamacare.

While there is no legislative text yet, members in the caucus are moving quickly to seize the defeat of a Senate bill last Friday to garner broader support for their proposals -- and to force the GOP to ditch its quest to gut the current health care law once and for all.

The group's proposal includes mandatory funding for cost-sharing reduction payments; the creation of a stability fund; a repeal of the medical device tax; and to raise the threshold of the employer mandate so that companies with 500 employees or more, rather than 50, are required to provide workers with health insurance.

New Jersey Rep. Josh Gottheimer, the Democratic leader of the Problem Solvers Caucus, acknowledged that its initial proposal "does not attempt to do everything" -- but that it's a start.

"Instead of just focusing on killing the ACA, we're focused on how to fix it in a smart way," Gottheimer said on Monday. "When (Sen. John) McCain said on the floor it's time to work together like the country wants -- that had a big influence on our group. It was a shot in the arm."

The effort comes from Republican and Democratic lawmakers representing the most competitive districts across the country.

Rep. Martha McSally, R-Arizona, stressed the importance of the group's bipartisan approach as well as its goal to stabilize the individual market.

"The big headline here is: Democrats, Republicans trying to find a way forward. We're not going to solve everything, but we're trying to deal with the problem at hand, and that's exactly what we did," McSally, who voted in favor of the House health care bill, told CNN's Wolf Blitzer on Tuesday.

"So these are singles and doubles. It's not a home run for everybody, but we're here to govern," she added.

There are barriers ahead.

House Speaker Paul Ryan's spokeswoman made it clear that the bipartisan health care proposals were not moving anytime soon in the House.

"While the speaker appreciates members coming together to promote ideas, he remains focused on repealing and replacing Obamacare," AshLee Strong said.

At the same time, others in their party are just as insistent that it's time for the party to leave a comprehensive health care overhaul behind and focus on smaller fixes that Democrats can get behind.

CNN's MJ Lee, Deidre Walsh and Noa Yadidi contributed to this report.

Read the rest here:

Senator announces bipartisan health care hearing on Obamacare - CNN

After Health Care Victory, Senate Democrats Seek Compromise on Tax Plan – New York Times

Senator Chuck Schumer, the minority leader, and Senator Ron Wyden, the ranking Democrat on the Senate Finance Committee, organized the drafting of the letter, which lays out their priorities. Three Democratic senators who are up for re-election next year Joe Donnelly of Indiana, Joe Manchin III of West Virginia and Heidi Heitkamp of North Dakota did not sign the letter. They could be ripe targets for Republicans looking for Democrats to get on board with their tax plan.

Despite the outreach, bipartisanship will not come easy.

On taxes, Democrats tend to favor raising taxes on the rich to pay for cuts that would reduce tax rates for middle-income families. The parties are in closer agreement on changes to the corporate tax system, but Democrats argue that the cuts Republicans are proposing are far too deep.

In the conditions laid out in their letter, the Democrats insisted that changes to tax laws not increase the tax burden on the middle class and that the wealthiest 1 percent of taxpayers not see their tax bills shrink.

They also insisted that Republicans return to regular order and not try to push a tax bill through Congress using budget reconciliation rules that require only a simple majority in the Senate.

Finally, they want a rewrite of the tax code that does not add to the deficit and is not paid for with cuts to programs such as Medicare, Medicaid and Social Security.

For much of this year, Democrats have criticized the proposed tax policies of Republicans as giveaways to the rich. It was clear on Tuesday that Republicans are not eager to let Democrats meddle with their plans for a tax overhaul, even if they would welcome a few of their votes.

We will need to use reconciliation because we have been informed by the majority of the Democrats in a letter I just received today that most of the principles that would get the country growing again, theyre not interested in addressing, Mr. McConnell said, leaving the option for Democrats to support a Republican-led tax plan. So I dont think this is going to be 1986 when you had a bipartisan effort to scrub the code.

For its part, the Trump administration has been more vocal this week about the importance of attracting some Democrats to its tax plan. At a gathering on Monday of conservative activists sponsored by Americans for Prosperity, the political network of the Koch brothers, Marc Short, the White House legislative affairs director, made the case that Democrats need to be brought into the fold. The Republican majority in the Senate, he said, was too slim for party members to count only on one another.

We ask your help, actually, reaching out to Democrats as well, Mr. Short said, noting the ones who are coming up for re-election. If they hear from their constituents that they need tax reform, thats going to be a very strong selling point.

It remains unclear how enthusiastic Democrats really would be to make compromises with Republicans that would allow Mr. Trump to score a major legislative victory. In the battle over the Affordable Care Act, even potentially vulnerable Democratic senators from states that the president won last year held firm in their opposition to the repeal of the health care law.

Relegated to the minority, however, Democrats are trying to stake out the moral high ground. Mr. Schumer warned on Tuesday that Republicans could suffer the same fate on taxes that they did on health care if they continue to operate alone.

Theres real potential for bipartisan support on tax reform, but I think our Republican colleagues, dictated by the Koch brothers hard right wing of their party, is running away from it, Mr. Schumer said. They say tax reform is hard, and it is. But its a lot harder if Republicans try to do it all by themselves.

Cooperation between the parties will be necessary for Congress to deal with more immediately pressing legislative priorities. The debt ceiling must be lifted by the end of September, and Mr. Schumer, Mr. McConnell and Treasury Secretary Steven Mnuchin huddled on Tuesday morning to discuss the way forward.

Although Mr. Mnuchin and Democrats want a clean lift of the statutory borrowing limit, many Republicans are pushing for spending cuts or changes to budget process to be linked to any legislation.

No breakthrough was made on that issue.

A version of this article appears in print on August 2, 2017, on Page A11 of the New York edition with the headline: Democrats Make Overture To G.O.P. on Tax Overhaul.

Go here to read the rest:

After Health Care Victory, Senate Democrats Seek Compromise on Tax Plan - New York Times

Most patients in US have high praise for their health care providers – Pew Research Center

(Jeff Greenberg/UIG via Getty Images)

While many physicians in the United States report frustrations with their work, the public continues to hold health care providers in high regard.

Nearly nine-in-ten Americans (87%) who have seen a health care provider in the past year say their concerns or descriptions of symptoms were carefully listened to, and 84% say they felt their provider really cared about (their) health and well-being, according to a Pew Research Center survey conducted in spring 2016. Just 23% of patients said they felt rushed by their health care provider, and even fewer (15%) felt confused about instructions they got for treatment or at-home care.

These findings come despite a range of negative experiences reported by health care providers themselves. Professional burnout, for example, is reportedly on the rise among physicians due to long work hours and excessive administrative burdens. Pediatricians find it harder to do their jobs as they confront a growing number ofparents who are hesitant to vaccinate their children.

Adding to this pressure, the medical personnel at the Centers for Disease Control and Prevention have had to cope with some 750 potentially serious health threats in the past two years, even as the agency faces budget uncertainties in the year ahead.Medical professionals and other stakeholders also have beenshut outof congressional deliberations about repealing and replacing the Affordable Care Act. Meanwhile, their own patients have grown more critical about the countrys health care system: A2014 Pew Research Center surveyfound that just 26% of adults say U.S. health care is above average or the best in the world, down from 39% in 2009.

Health care providers are not the only medical professionals who receive favorable ratings from the public. Medical scientists are likewise held in high esteem.

For example, in a 2016 Pew Research Center survey, 84% of Americans expressed at least a fair amount of confidence in medical scientists to act in the best interests of the public. And a 2013 survey revealed that 66% of Americans believe doctors contribute a lot to the well-being of society a higher rating than for the clergy, journalists and business executives.

Moreover, although pediatricians are confronting an increasing number of vaccine-hesitant parents, the majority of the U.S. public still wants them engaged in the issue. Nearly three-quarters of U.S. adults (73%) believe that medical scientists should have a major role in policy decisions related to childhood vaccines.

Topics: Work and Employment, Health Care, Health, Science and Innovation

Read this article:

Most patients in US have high praise for their health care providers - Pew Research Center

The Latest: States get involved in health care court case – ABC News

The Latest on the Republican effort to repeal and replace the Obama health law (all times EDT):

8:30 p.m.

A federal appeals court in Washington has agreed to let a group of states get involved in a lawsuit over government payments to insurers as part of the Obama administration's health care law. It's an intervention House Republicans had opposed.

House Republicans trying to thwart the Affordable Care Act sued the administration in federal court in 2014, arguing the law lacked specific language appropriating the "cost-sharing" subsidies. A district court judge agreed with House Republicans but the case was appealed to the U.S. Court of Appeals for the District of Columbia Circuit.

On Tuesday, the court allowed a group of state attorneys general to join in the case, in defense of the subsidies. In an order, the court says the states have "demonstrated the appropriateness of their intervention."

7 p.m.

There are signs of a modest bipartisan effort to buttress health insurance markets, four days after the GOP effort to uproot and reshape the Obama health care law crumpled in the Senate.

The Republican chairman of the Senate health committee, Tennessee's Lamar Alexander, says he'll seek bipartisan legislation extending for one year federal payments to insurers that help millions of low- and moderate-income Americans afford coverage.

President Donald Trump has threatened to halt those subsidies in hopes of forcing Democrats to make concessions. Top Senate Democrat Chuck Schumer of New York says that's "not what an adult does."

3:05 p.m.

Senate Majority Leader Mitch McConnell is answering President Donald Trump's call for a change in Senate rules with a dose of political reality.

The Republican leader told reporters on Tuesday that the reason for the collapse of health care legislation was not Democrats in opposition, but rather, "we didn't have 50 Republicans."

Over the weekend, Trump tweeted that Republicans should change the rules on legislation and reduce the 60-vote threshold to eliminate possible filibusters. His tweets came after the failure of health care legislation on a razor-thin margin of 51-49 on Friday.

McConnell said there are not enough votes to change the rules in the Senate. He said, "The votes are simply not there."

2:55 p.m.

The chairman of the Senate health committee says he wants his panel to approve a one-year extension of federal payments to insurers so they can curb out-of-pocket health care costs for millions of Americans.

Tennessee Republican Sen. Lamar Alexander says he wants his committee to pass a bipartisan bill doing that by mid-September. He says he's asked President Donald Trump to continue the payments in August and September to give his panel time to do its work.

Trump has called those payments bailouts for insurers. He's threatened to halt them to force Democrats to negotiate with him over repealing and replacing the Obama health care law.

Democrats, the insurance industry and some Republicans say halting those subsidies would roil insurance markets and boost premiums for many consumers.

12:40 p.m.

The No. 2 Senate Republican leader seemed to suggest that the two parties should try working together on health care.

Sen. John Cornyn of Texas did not specify what issues the two sides could address together. But his comments followed last week's crumpling of the Senate Republican effort to repeal and replace President Barack Obama's health care law.

In remarks on the Senate floor Tuesday, Cornyn cited "fragile majorities" in the Senate and said "we are forced to work together to try to solve these problems." He added that he believes bipartisan solutions "tend to be more durable."

Along those lines, Senate GOP health committee chairman Lamar Alexander of Tennessee discussed health care Tuesday at a private meeting with the panel's top Democrat, Patty Murray of Washington.

12 p.m.

The Senate's top Democrat says President Donald Trump's threats to block federal payments to insurers are "not frankly what an adult does" and would boost consumers' premiums.

Senate Minority Leader Chuck Schumer made the comments as Washington waits to see if Trump will halt the expenditures.

President Barack Obama's law requires insurers to lower out-of-pocket costs for millions of lower- and middle-income consumers. A court has ruled that Congress hasn't properly authorized the money. Trump has continued the payments until now.

Trump and Republicans call the expenditures bailouts for insurers.

The insurance industry notes they're legally required to reduce many customers' costs. It says blocking the federal payments would cause them to boost premiums by around 20 percent.

Schumer says Trump would be to blame if that happens.

3:30 a.m.

Top Senate Republicans think it's time to leave their derailed drive to scrap the Obama health care law behind them.

And they're tired of the White House prodding them to keep voting on it until they succeed.

Several GOP leaders say that at least for now, they see no clear route to the 50 votes they'd need to get something anything recasting President Barack Obama's health care statute through the Senate.

Their drive crashed last week. And their mood didn't improve after a weekend of tweets by President Donald Trump saying they "look like fools" and White House budget chief Mick Mulvaney using TV appearances to say they should continue voting.

No. 2 Senate Republican John Cornyn of Texas says Mulvaney should "let us do our jobs."

Read the rest here:

The Latest: States get involved in health care court case - ABC News

Iran: Opposition Figures Denied Health Care – Human Rights Watch

Presidential candidate Mirhossein Mousavi (R) and his his wife Zahra Rahnavard cast their ballots during the Iranian presidential election in southern Tehran June 12, 2009.

The former candidates, Mehdi Karroubi and Mir Hossein Mousavi, and Zahra Rahnavard, an author and activist who is Mousavis wife, have been under house arrest in Tehran since February 2011. Iranian authorities should immediately provide them with unrestricted access to adequate health care.

Iranian officials have deprived Mousavi, Karroubi, and Rahnavard of their most basic rights for more than six years, all without a judicial order or even the pretense of due process, said Sarah Leah Whitson, Middle East director at Human Rights Watch. Irans authorities should stop denying Mousavi and Karroubi the care they need, grant immediate access to a specialist medical facility, and end their house arrest.

On July 24, 2017, Mohammad Taghi Karroubi, Karroubis son, posted on Twitter that his father had been transferred to a hospital in Tehran after suffering an abnormally low heart rate. On July 28, Mohammad Taghi Karroubi confirmed in correspondence with Human Rights Watch that Intelligence Ministry officials had ordered Karroubis transfer back to his house the day before, against Karroubis doctors advice.

On July 28, Karroubis family wrote an open letter published in several Persian-language media outlets stating that Karroubi had suffered from a serious heart issue the day after he was moved back to his house. On July 30, Hossein Karroubi, another of Karroubis four sons, reported that authorities transferred his father back to a hospital in Tehran, where he is being treated.

Mohammad Taghi Karroubi told BBC Persian that the authorities treatment over the last several years has instilled fear among his family that the Ministry of Intelligence has appointed someone to the case who sees ending these detainees lives as his duty. The family has said they hold President Hassan Rouhani responsible for Karroubis wellbeing.

On July 26, the Kalameh, a pro-reform news website, reported that according to Mousavis daughters, Zahra and Narges, the former presidential candidate and prime minister is suffering from high blood pressure, dizziness, and chronic kidney problems. On July 27 and 28, Zahra and Narges Mousavi posted on their Twitter accounts that they have not been able to get any information on their fathers medical condition since their visit with him on July 25.

Several members of parliament, including Mahdmoudi Sadegh and Elias Hazari from Tehran, reported that they have tried to visit Karroubi in the hospital but that authorities have denied them permission.

Officials placed the two former presidential candidates and their wives, Zahra Rahnavard and Fatemeh Karroubi, under house arrest on February 14, 2011, in response to the opposition figures call for demonstrations in support of popular uprisings across the Middle East. While the authorities have released Fatemeh Karroubi, the other three remain detained. During six-and-a-half years of detention, officials have regularly deprived Mousavi and Karroubi from receiving the regular check-ups doctors had recommended for serious medical conditions.

Iranian officials, including Irans judiciary, have failed to provide any legal justification for the opposition figures continuing arbitrary detention. President Rouhani promised during his 2013 presidential campaign to lift the former candidates house arrest, but has not, and there is little available information about his efforts, if any, to free them.

Ali Motahari, a parliament member from Tehran who has repeatedly protested the house arrest in his speeches, said several times that the Supreme Leader, Ayatollah Ali Khamenei, is in favor of continuing the house arrest.

In August 2012, the United Nations Working Group on Arbitrary Detention, a body of five independent experts acting under the UN Human Rights Council, issued an opinion that the detentions are arbitrary (and thus prohibited), and recommended that the Iranian government release the detainees immediately and compensate them for their wrongful imprisonment.

Human Rights Watch has repeatedly called on Irans authorities, including Rouhani, to push for the release of the opposition figures and give them adequate access to medical care.

As President Rouhani begins his second term on August 5, he should demonstrate that he takes his promises to his fellow citizens for more rights and legal protections seriously, Whitson said. A good place to start would be to free Mehdi Karroubi, Mir Hossein, and Zahra Rahnavard from house arrest and to see that they get the health care they need.

More here:

Iran: Opposition Figures Denied Health Care - Human Rights Watch

Gene Editing Is Revolutionizing Medicine but Causing a Government Ethics Nightmare – Newsweek

Updated | Late last week, reports emerged that scientists in Oregon had used gene-editing technology, known as CRISPR-Cas9, to edit a human embryo. While research like this is already occurring in China and Great Britain, this is the first time scientists in the U.S. have edited an embryo.

The move raises thequestion of whether regulations are strict enough in the U.S. Both Congress and the National Institutes of Health have explicitly said they would not fund research that uses gene-editing to alter embryos. But laws and guidelines are not keeping pace with this fast-moving and controversial work.

CRISPR is an experimental biomedical technique in which scientists are able to alter DNA, such as change the misspellings of a gene that contributes to mutations. The technology has the potential to reverse and eradicate congenital diseases if it can be used successfully on a developing fetus.

Tech & Science Emails and Alerts - Get the best of Newsweek Tech & Science delivered to your inbox

Here's how CRISPR gene editing works. REUTERS

The news frenzy that followed this announcement was based on a leak from unknown sources. Initial reports emerged from a number of less known sources, including MIT Technology Review, that Shoukhrat Mitalipov of Oregon Health and Science University used the technology to change the DNA of not just one, but a number of embryos. But the news stories about this research werent based on a published study, which means they dont provide the full picture. No one yet knows what the researchers did or what the results were.

Until now, most of the breakthrough research on CRISPRaside from the discovery itself, which is attributed to multiple research groups in the U.S. has occurred in China. InApril 2015, Chinese scientists reported that theyd edited the genome of human embryos, a world first, in an attempt to eliminate the underlying cause of a rare blood disorder.

Researchers there have also been experimenting with CRISPR technology to treat cancer. Last spring, a team of scientists at Sichuan Universitys West China Hospital used the approach to modify immune cells in a patient with an aggressive form of lung cancer. The researchers altered genes in a bid to empower the cells to combat the malignancy. Another group of Chinese scientists tried changing genes in blood that were then injected into a patient with a rare form of head and neck cancer to suppress tumor growth.

Despite potential of CRISPR to cure fatal diseases, the technology has fast become one of the most significant challenges for bioethicists. Some people view its power as potentially dangerous because it could allow scientists to cherry-pick genetic traits to create so-called designer babies.

Arthur Caplan, a professor of bioethics at New York University's Langone Medical Center and founding director of NYULMC's division of medical ethics thinks the fears are overblown. Gene-editing technology, says Caplan, is nowhere near this sci-fi fantasy.

If you would compare this to a trip to Mars, you're basically launching some satellites, says Caplan. He suggests that much of the media coverage on CRISPR is melodramatic, including last weeks coverage of researchers meddling with an embryo. We haven't shown that you can fix a disease or make someone smarter.

Lack of Guidelines

CRISPR technology isnt ready for clinical use, whether to stop serious genetic diseases or simply make brown eyes blue. But geneticists are working toward these goals, and the scientific community is ill-prepared to regulate this potentially powerful technology.

So far guidelines for using CRISPR are minimal. In 2015, the National Institutes of Health issued a firm statement. Advances in technology have given us an elegant new way of carrying out genome editing, but the strong arguments against engaging in this activity remain, the NIH said in its statement. These include the serious and unquantifiable safety issues, ethical issues presented by altering the germline in a way that affects the next generation without their consent, and a current lack of compelling medical applications justifying the use of CRISPR/Cas9 in embryos.

But although the NIH wont back CRISPR research for embryo editing, that doesnt mean such research is prohibited in the U.S. Private organizations and donors fund researchers. Caplan suspects this is how the team in Oregon managed to carry out their experiment.

In February 2017, the National Academy of Sciences and the National Academy of Medicinetwo leading medical authorities that propose medical and research guidelines for a wide range of research and medical topics issued sweeping recommendations for the use of CRISPR technology. In their joint Human Genome Editing: Science, Ethics, and Governance report, the panel of experts deemed the development of novel treatments and therapies an appropriate use of the technology. The recommendations also approve investigating CRISPR in clinical trials for preventing serious diseases and disabilities and basic laboratory research to further understand the impact of this technology.

The authors of the report caution against human genome editing for purposes other than treatment and prevention of diseases and disabilities. But the line between treatment and enhancement isnt always clear, says Caplan. And policing so-called ethical uses of CRISPR technology will be increasingly difficult because single genes are responsible for a myriad diseases and traits. You don't realize that you're changing DNA in places you don't want to, he says.

A source familiar with the controversial Oregon research reported last week told Newsweek that a major journal will publish a paper on the work by the end of this week. According to The Niche, a blog produced by the Knoepfler Lab at University of California Davis School of Medicine in Sacramento, California, the paper is slated to be published in Nature . Mitalipov did not respond to Newsweek s requests for comment or confirmation.

Caplan hopes that publication of the paper will initiate further discussion about the ethics of experimenting with CRISPR including practical measures such as a registry for scientists conducting studies through private funding. We need to have an international meeting about what are the penalties of doing this, he says. Will you go to jail or get a fine?

This story has been updated to note that the initial report of the CRISPR research in Oregon was based on a leak, but did not necessarily misconstrue the research.

Original post:

Gene Editing Is Revolutionizing Medicine but Causing a Government Ethics Nightmare - Newsweek

In US first, scientists edit genes of human embryos – Indiana Gazette

For the first time in the United States, scientists have edited the genes of human embryos, a controversial step toward someday helping babies avoid inherited diseases.

The experiment was just an exercise in science the embryos were not allowed to develop for more than a few days and were never intended to be implanted into a womb, according to MIT Technology Review, which first reported the news.

Officials at Oregon Health & Science University confirmed Thursday that the work took place there and said results would be published in a journal soon. It is thought to be the first such work in the U.S.; previous experiments like this have been reported from China. How many embryos were created and edited in the experiments has not been revealed.

The Oregon scientists reportedly used a technique called CRISPR, which allows specific sections of DNA to be altered or replaced. It's like using a molecular scissors to cut and paste DNA, and is much more precise than some types of gene therapy that cannot ensure that desired changes will take place exactly where and as intended. With gene editing, these so-called "germline" changes are permanent and would be passed down to any offspring.

The approach holds great potential to avoid many genetic diseases, but has raised fears of "designer babies" if done for less lofty reasons, such as producing desirable traits.

Last year, Britain said some of its scientists could edit embryo genes to better understand human development.

And earlier this year in the U.S., the National Academy of Sciences and National Academy of Medicine said in a report that altering the genes of embryos might be OK if done under strict criteria and aimed at preventing serious disease.

"This is the kind of research that the report discussed," University of Wisconsin-Madison bioethicist R. Alta Charo said of the news of Oregon's work. She co-led the National Academies panel but was not commenting on its behalf Thursday.

"This was purely laboratory-based work that is incredibly valuable for helping us understand how one might make these germline changes in a way that is precise and safe. But it's only a first step," she said.

"We still have regulatory barriers in the United States to ever trying this to achieve a pregnancy. The public has plenty of time" to weigh in on whether that should occur, she said. "Any such experiment aimed at a pregnancy would need FDA approval, and the agency is currently not allowed to even consider such a request" because of limits set by Congress.

One prominent genetics expert, Dr. Eric Topol, director of the Scripps Translational Science Institute in La Jolla, Calif., said gene editing of embryos is "an unstoppable, inevitable science, and this is more proof it can be done."

Experiments are in the works now in the U.S. using gene-edited cells to try to treat people with various diseases, but "in order to really have a cure, you want to get this at the embryo stage," he said. "If it isn't done in this country, it will be done elsewhere."

There are other ways that some parents who know they carry a problem gene can avoid passing it to their children, he added. They can create embryos through in vitro fertilization, screen them in the lab and implant only ones free of the defect.

Dr. Robert C. Green, a medical geneticist at Harvard Medical School, said the prospect of editing embryos to avoid disease "is inevitable and exciting," and that "with proper controls in place, it's going to lead to huge advances in human health."

The need for it is clear, he added: "Our research has suggested that there are far more disease-associated mutations in the general public than was previously suspected."

Hank Greely, director of Stanford University's Center for Law and the Biosciences, called CRISPR "the most exciting thing I've seen in biology in the 25 years I've been watching it," with tremendous possibilities to aid human health.

"Everybody should calm down" because this is just one of many steps advancing the science, and there are regulatory safeguards already in place. "We've got time to do it carefully," he said.

Michael Watson, executive director of the American College of Medical Genetics and Genomics, said the college thinks that any work aimed at pregnancy is premature, but the lab work is a necessary first step.

"That's the only way we're going to learn" if it's safe or feasible, he said.

See more here:

In US first, scientists edit genes of human embryos - Indiana Gazette

How precision medicine, immunotherapy are influencing clinical trial design for cancer drugs – MedCity News

Newfound understanding of the biology of cancer has spurred a wave of oncology drug approvals, creating previously unheard of treatment success. At the same time, this degree of success leads to a rapidly shifting competitive landscape, presenting unique challenges for pharma companies planning cancer clinical trials. What steps can the pharma community take to remain flexible and responsive in this new Golden Age of smarter therapies?

An accelerated pace of approvals

Oncology research and improvements in technology have ushered in a new era of more targeted therapeutics based on the mechanisms that drive cancer. Technological advances in tumor imaging and next-generation sequencing have sped the development of precision medicines, treatments that target specific genetic markers rather than relying purely on cytotoxicity. The decreased cost of analysis has led to increased accessibility of genetic data, allowing leading cancer hospitals to use NGS to guide treatment decisions for new cancer patients based on their cancers specific genetic makeup. In addition, the field is seeing tremendous strides in immunotherapy approaches, which seek to activate the immune systemto defeat cancer cells.

In response to the early success of precision medicines and immunotherapies, the U.S. Food and Drug Administration is approving drugs faster and more frequently. In 2014, all but one oncology drug approved by the FDA received some form of expedited designation. By the following year, more oncology drugs were approved by the FDA than ever before.

The rapid pace of new drug approvals has, in turn, increased the pace of changes to the standard of care, now determined as much by biomarkers as by histology. New data continues to shape the current clinical practice guidelines. The National Comprehensive Cancer Network has updated guidelines for lung cancer five times since they were first issued in late 2016.

The impact on pharma

The accelerated pace of drug approvals for cancer has created a flurry of activity in the pharma community. As of 2014, there were nearly 800 cancer drugs in development. and in 2017 more than 12,000 active cancer clinical trials. Looking just at the field of immuno-oncology and checkpoint inhibitors, which have exploded onto the market in recent years, there are over 750 active studies with checkpoint combinations today. Conducting cancer clinical trials has always been complex, but planning successful clinical trials amid a rapidly shifting oncology landscape presents unique challenges for pharma sponsors.

To provide useful results, clinical trials should use the highest standard of approved care for their participants,but the standard of care in oncology is constantly shifting. As treatments target increasingly specific disease states, clinical trial design must evolve to generate enough data from relatively small sample populations. In an increasingly competitive space, pharma sponsors are tasked with finding the quickest ways to gather safety and efficacy data that satisfies FDA requirements.

Now more than ever, the pharma community must become flexible and responsive to a rapidly changing marketplace. Although sponsors can attempt to anticipate future treatment approvals and incorporate them into statistical models, there is a limit to how far into the future they are able to forecast. Sponsors may, therefore, wish to consider the following ways to design their clinical trial protocols with a degree of adaptability to have the greatest chance of success.

Adjust inclusion/exclusion criteria

In order to recruit patients more quickly, sponsors can adjust the inclusion/exclusion criteria to be less strict. However, this approach may yield a heterogeneous population, which might have an undesired effect on data quality and statistical efficacy.

Allow investigators choice

For trials that combine or compare an investigational drug with the existing standard of care that is likely to change, sponsors may need to consider letting investigators choose from a menu of comparators. The statistical and logistic implications, as well as the timeline, are important to consider.

Plan for critical amendments

Portions of a clinical trial can be completed before a new therapy is generally available or reimbursed. Although making changes to the protocol during the course of a clinical study are generally not desired because of added time and cost, there are certain cases where making critical amendments is necessary.

If first-line approval for a drug is already being pursued, sponsors can take advantage of a gap in therapeutic options by adding another arm to their trials that demonstrateeffectiveness as a second-line therapy.

Use innovative trial designs

Changes to protocol designs are also influencing how quickly enough evidence can be generated for the FDA to grant approval. Two innovative new designs are basket trials and umbrella trials. In a basket trial, patients are recruited based on the genetic makeup of their tumor rather than tumor histology. The recent FDA approval of pembrolizumab was the first approval based on a common biomarker rather than the location in the body where the tumor originated. Umbrella trials allow researchers to test multiple indications and combinations for a given therapy, with the potential to spin any arm off as its own registrational component.

Its an exciting time to be in cancer research and to watch some of these therapies move rapidly from clinic to improving the lives of patients. Sponsors play an important role during development by spearheading innovation, staying flexible, and planning accordingly for the rapid pace.

Photo: DrAfter123, Getty Images

Original post:

How precision medicine, immunotherapy are influencing clinical trial design for cancer drugs - MedCity News

Chiesi hands back gene therapy to uniQure | BioPharma Dive – BioPharma Dive

Dive Brief:

Even as gene therapies are being touted as the next wave of innovation that could offer cures for certain genetic conditions, it remains to be seen whether these products are actually commercially viable. There has yet to be a gene therapy approved in the U.S. (although Spark Therapeutics' application is pending), but two of the transformative drugs have been on the market in Europe.

Yet neither of those commercially available gene therapies have found much success. GlaxoSmithKline plc. said just last week it is looking to move away from its rare disease portfolio, including the gene therapy Strimvelis. Meanwhile, uniQureannounced back in April it would not renew the marketing authorization application in Europe for its already-approved gene therapy Glybera.

This latest move by Chiesifurther exemplifies the challenges gene therapy producers face. The announcement ends a deal which has been in place since 2013. Chiesisaid in a statement that the decision was "driven by recent changes in our strategic priorities."

uniQuretried to put brave face on the news, but partnership exits are rarely good news for a biotech.

"By regaining unencumbered, global rights to a late-stage program that has demonstrated significant clinical benefit for patients with hemophilia B, we believe uniQure is better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline and take advantage of new potential opportunities related to the program," said CEO Matthew Kapusta.

The company recently announced positive developments in a Phase 1/2 trial of AMT-060, which supported further expansion of the eligibility of the adeno-associated virus 5 (AAV5) gene therapy to nearly all patients with hemophilia B. Meanwhile, investors are paying close attention to Spark's gene therapy for hemophilia B, which is also in early-to mid-stage development.

Read more from the original source:

Chiesi hands back gene therapy to uniQure | BioPharma Dive - BioPharma Dive

Philly drug maker seeks approval in EU for gene therapy – Philly.com

Philadelphia gene therapy company Spark Therapeutics has applied to the European Medicines Agency for approval to sell its treatment of rare inherited blindness in the European Union.

The experimental therapy, Luxturna, or voretigene neparvovec, is under priority review with the U.S. Food and Drug Administration, with a possible approval date of Jan. 12, 2018.

Spark was spun out of Childrens Hospital of Philadelphia, based on research led by Katherine A. High, Sparks cofounder, president, and chief scientific officer. If approved, it would be the first gene therapy for a genetic disease in the United States.

With Luxturna now in regulatory review on both sides of the Atlantic, we are building out our medical and commercial infrastructure to bring the drug to patients, said John Furey, Sparks chief operating officer. For the first time, adults and children, who otherwise would progress to complete blindness, have hope for a potential treatment option that may restore their vision, he said.

About 3,500 people in the United States and Europe live with the disease.

The review period will begin in Europe once the agency validates the application, Spark said.

Published: August 1, 2017 3:01 AM EDT | Updated: August 1, 2017 11:40 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day. We're thankful for your support in every way.

See original here:

Philly drug maker seeks approval in EU for gene therapy - Philly.com

New Gene Therapy to Fix Dystrophin Deficiency in DMD Shows Promise in Mice, Study Shows – Muscular Dystrophy News

Researchers at the University of Missouri have developed a new method to efficiently deliver the correct form of dystrophin gene to muscles as a way to correct the faulty gene that characterizes Duchenne muscular dystrophy (DMD), a mouse study shows.

Their study, A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy, appearedin the journal Molecular TherapyMethods & Clinical Development.

DMD is caused by a modification of the gene that encodes the dystrophin protein, which is essential for normal muscle activity. Such mutations interfere withproduction of the functional protein, severely affecting muscle fiber structure and strength.

Correcting the faulty gene could potentially treatthis disease. Several attempts atgene therapyhave been tried, but all have failed to efficiently reverse all DMD symptoms.

Gene therapy commonly uses vectors basedviral genetic sequences to achieve the desired gene transfer capacity. The therapeutic potential of these techniques rely not only on the delivery system, but also on the sequence of the gene of interest that is used. In this case, smaller versions of dystrophin known asmicrodystrophinmust be used, since its natural form is just too big to be useful in gene therapy.

There have been other gene-transfer vectors attempted in the past (such as adenoviral vector, herpes simplex virus and plasmid), but they have largely been unsuccessful due to the complexity of the disease, challenges associated with delivery, and the large size of the native dystrophin gene, the studys senior author, Dongsheng Duan, said in a news release.

Duans team used an engineered form of the adeno-associated virus (AAV) vector to replace the damaged gene specifically in the muscles.

Researchers alsoused a version of the dystrophin gene that can potentiallyminimize the toxicity signs commonly associated with such methods, such as inadequate blood supply and fatigue during muscle contraction. This AAV viral vector has also been used in the past, but this is the first time researchers have combined it with such a version of dystrophin.

This strategy boostedlevels of dystrophin protein in the muscles of mice models of DMD, and significantly reduced some disease symptoms. Yet researchers could not accurately measure the impact of this new potential therapy to correct DMD-associated effects on the hearts of the animals.

Human studies have shown that one-time intramuscular injection of an AAV vector can result in the expression of a therapeutic protein for many years. For example, a study showed Factor IX expression for 10 years in a hemophilia patient, Duan said. In preclinical studies in murine and canine models, we have also observed persistent multiyear microdystrophin expression from AAV vectors. In the case of mice, a single injection can lead to microdystrophin expression throughout the lifespan.

Read the original post:

New Gene Therapy to Fix Dystrophin Deficiency in DMD Shows Promise in Mice, Study Shows - Muscular Dystrophy News

Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic Partnership – Business Wire (press release)

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution Co, Ltd. (GTRI), a corporation with the mission of developing and delivering of the safest and most efficient gene therapies, today announced that the companies have completed a manufacturing and collaboration partnership joint venture (JV) to advance adeno-associated virus (AAV) gene therapies. The JV was initiated earlier this year in connection with a grant from the Japanese Ministry of Trade, Economics and Industry (METI) and Japan External Trade Organization (JETRO) for the development of a state-of-the-art AAV manufacturing facility in Japan. GTRI was co-founded by Professor Shin-ichi Muramatsu, M.D., a leading pioneer in gene therapy who has performed basic science and clinical research in the field for over two decades.

The JV, headquartered in Japan, will initially focus on developing and manufacturing AAV gene therapy vectors using Sf9 baculovirus and HEK293 mammalian cell systems and operate a process development and production facility located in the Tokyo area designed to meet international manufacturing standards, including cGMP, GCTP and PIC/S GMP requirements. Agilis and GTRI will also collaborate to expedite the development, approval and commercialization of select gene therapies in specific CNS diseases. Terms of the joint venture were not disclosed.

We are pleased to collaborate with Agilis to leverage each organizations capabilities and know-how, advance the manufacturing state-of-the art for gene therapy, and develop novel gene therapies, commented Katsuhito Asai, Chief Executive Officer of GTRI and a Director of the joint venture. Our partnership will seek to capitalize on the strong recent progress in the field of gene therapy and expedite the development of innovative gene therapies for patients in need, with a major emphasis on the quality production of safe, effective therapeutics.

We are thrilled to partner with GTRI, said Mark Pykett, Agilis CEO and a Director of the joint venture. We believe that our partnership will enhance the efforts of both organizations, build important shared production capabilities, and accelerate development and commercialization of important gene therapies. We look forward to working with GTRI on a range of initiatives.

Agilis Biotherapeutics

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targeting and restoration of lost gene function to achieve long-term efficacy. Agilis rare disease programs are focused on gene therapy for AADC deficiency, Friedreichs ataxia, and Angelman syndrome, all rare genetic diseases that include neurological deficits and result in physically debilitating conditions.

We invite you to visit our website at http://www.agilisbio.com

About GTRI

GTRI, a bio-tech venture in Japan, was founded in May 2014 based on the pioneering research of Dr. Shin-ichi Muramatsu, focusing on gene therapy using AAV vector as the leading company in Japan in this field. Its pipeline includes more than 20 diseases, targeting CNS diseases and monogenic disorders, such as Parkinsons disease, AADC deficiency, ALS, Alzheimers disease, spinocerebellar degeneration, Tay-Sachs disease, GLUT1 deficiency, and others.

Dr. Muramatsu, PhD, MD, of Jichi Medical University, is one of the top researchers of AAV vectors and AAV-mediated gene therapy in the world. He originated AAV3 in 1995 during his research at the NIH, USA, and afterwards developed his original modified AAV3/9 in Japan, which enables to deliver the gene of interest effectively in CNS through the blood-brain barrier.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Go here to read the rest:

Agilis Biotherapeutics and Gene Therapy Research Institution Enter into Strategic Partnership - Business Wire (press release)

4 Big Trends That Will Shape CRE: A Futurist’s Guide – Commercial Property Executive

Volvos surprise announcement that it will phase out the internal combustion engine by 2019 should be a wake-up call across industries that disruptive technology is already impacting short-term business planning. Anticipating how the economy and human behavior will be reshaped in the years ahead is an important exercise that should inform business leaders decisions and help position their businesses to more readily adapt to the future.

Commercial real estate is not disconnected from the challenges and opportunities posed by technology. Quite the opposite; it will be at the epicenter as outside forces impact how people live, commute, work and interact. As commercial real estate leaders, we should be mindful of how the developments were building now will be used in 10 or 15 years, when todays emerging technology has become tomorrows ubiquitous convenience.

Here are four technologies and trends that could shape commercial real estate in the not-too-distant future.

The University of Michigan is researching self-driving cars at a facility in Ann Arbor. (Image courtesy of the University of Michigan)

Fully self-driving cars arent too far from becoming a reality. In fact, Michigan authorized testing autonomous vehicles on public roads, and the University of Michigan will soon deploy autonomous vehicles around at its engineering campus in Ann Arbor.

While a single campus may seem like a small example, the University of Michigans research could soon open up new possibilities for people who would otherwise chafe at a long commute. If the car becomes a mobile workspace, driving to the office becomes productive work time and the distance traveled is less important. Its conceivable that the suburbs could become a magnet again for people looking for more affordable housing and access to amenities like golf courses, walking trails and better schools.

Flexible work arrangements and the normalization of teleworking could further accelerate a return to suburbia spurred by autonomous driving. These two converging trends may cause more peopleincluding aging millennials with school-aged childrento look beyond the urban cores and close-in suburbs for affordable and spacious housing.

If the sharing economy lives up to its hype, the implications for commercial real estate are enormous. Ride-sharing companies such as Uber and Lyft are already well-established, but driverless vehicles could transform these services from a convenient option to a groundbreaking alternative to car ownership.

As ride-sharing companies mature and autonomous vehicles drive down the cost of rides even further, will it even make financial sense for Generation Z to own cars? What does that do to the footprint and design of multifamily developments? If people can rent out their self-driving cars to a ride-sharing service while theyre at work, will there still be a need for massive parking garages connected to office towers? Could it open new development opportunities for sites now occupied by parked cars?

Herzog & de Meurons design for 1111 Lincoln Road in Miami reimagines the parking structure.

These trends could also drive the redevelopment of existing spaces. Herzog & de Meuron, the Swiss architectural firm, reimagined the parking garage with its groundbreaking structure at 1111 Lincoln Road in Miami. This mixed-use parking garage includes office space, storefronts, apartments, a SunTrust branchand yes, some parking. The striking design and creative use of space could be a viable model for existing garages that have outlived their usefulness as a place to park cars.

Virtual reality is arguably one of the most disruptive technologies on the horizon, and the applications are endless, from revolutionizing how people communicate across continents to allowing people to experience places in immersive ways.

Applying VR to commercial real estate would be relatively easy. Developers could take investors on tours of planned buildings before any dirt has been moved; brokers may offer tenants virtual tours to multiple properties in the span of an hourall from the comfort of an office; and developers and bankers can test the waters by taking focus groups on VR-aided visits to planned communities before a single dollar is spent.

VRs usefulness to the commercial real estate industry might seem like more of a novelty than necessity, but enterprising people will find ways to make it financially feasible and convenient.

Millennials are not monolithic in their behaviors, contrary to what some industry experts seem to suggest. While many in this generation desire an urban environment close to work and lifestyle amenities, they are also demonstrating an interest in owning single-family homes. Seventy percent of millennials see themselves in the suburbs with their next home, according to a 2016 PulteGroup study.

The emerging desire of millennials to own homes could signal challenges for the multifamily industry, especially if the trend accelerates, too much supply is on the market and Generation Z demonstrates a similar propensity for homeownership.

In the event of prolonged multifamily vacancies, how can investors make the most of their holdings? Could apartments be refashioned and sold as condos for seniors who desire more walkable communities? Might local and state governments offer incentives to convert apartments into affordable housing? Reimagining existing multifamily communities may be necessary in the years to come.

The imperfect exercise of predicting the impact of technology is no reason to avoid asking difficult questions. The business opportunities and uncomfortable possibilities presented by innovation, if properly considered, can be addressed or mitigated now if leaders have the foresight to imagine how thingsand peoplewill change.

Technology has already demonstrated its ability to impact commercial real estate; reduced demand for office space is only one of many examples. If the last decade has taught the commercial real estate industry anything, its that searching the horizon for trouble and opportunities to stay ahead of the next paradigm shift is a smart way to conduct business.

Kathleen Farrell is head of commercial real estate at SunTrust Banks Inc.

Read this article:

4 Big Trends That Will Shape CRE: A Futurist's Guide - Commercial Property Executive

Reviewers of Tesla’s Newest Vehicle Are Unanimous: The Model 3 Has No Competition – Futurism

In BriefThe first reviews of Tesla's Model 3 are in and they areresoundingly positive beyond expectations, even for thoseanticipating the world from the new model. Yes, the reviews arefilled with hyperbole and they're absolutely heartfelt, with thedetail to back them up. A Peerless Ride

As the Tesla Model 3 launch was imminent, Jack Stewart of Wired wrote, The arrival of Teslas Model 3 signals a new chapter in automotive history, one that erases 100-plus years of the gas engine and replaces it with technology, design, and performance hot enough to make electric vehicles more than aspirational to make [electric vehicles (EVs)] inspirational. But would it live up to its promise?

If youre still feeling skeptical about Teslas Model 3, the reviewers definitely arent. Heres what they have to say now that theyve driven it.

In a piece prefaced with, The Tesla Model 3 is here, and it is the most important vehicle of the century. Yes, the hyperbole is necessary, Kim Reynolds of Motor Trend raved: If anybody was expecting a typical boring electric sedan here, nope.

Magic, Im telling you. Magic. And this is the single-motor, rear-wheel-drive starting point. The already boggled mind boggles further at the mention of Dual Motor and Ludicrous, Reynolds continued. Have I ever driven a more startling small sedan? I havent. At speed, it gains a laser-alertness I havent encountered before [] [The] 2.0-liter Alfa Romeo Giulia [] feels like a wet sponge by comparison.

Ive driven all Teslas vehicles, Matthew Debord ofBusiness Insider wrote,But the Model 3 is something else [] [its] going to blow many, many minds. This is easily the most attractive entry-level luxury, all-electric car on the market[] I can safely say that the Model 3 has no competition.

[T]here isnt anybody whos going to sit in the drivers seat of this car and not want it, Debord continued. The Model 3 stokes immediate desire, and the lust lingers. That truly changes everything.

Peter Holley of The Washington Post gave a sense of the Model 3 as the car of the future, writing thatfrom the moment you sit inside the Model 3, you do sense that you have entered uncharted territory[] I attribute that feeling to the intuitive nature of the Model 3s minimalist design [and] the way the car seamlessly incorporates technology that is already second nature in many peoples everyday lives.

Its not so much that Tesla is ushering in the future, Holley argued. After riding in the Model 3, Im more inclined to think that Tesla is single-handedly pulling the automotive industry into the present the way anyone born before the Internet thought 2017 would look like decades earlier.

Charlie Turner of Top Gear explained the Autopilot experience: Our brief excursion also allowed us to test the Autopilot, a system that still feels like witchcraft. The levels at which the car is capable of processing information are staggering and if were honest its clearly concentrating a lot harder than most of us after a hard day at the office.

And both Engadget and Wired see the Model 3 and a sign of a new era in transportation. Engadgets Andrew Taratola wrote, While the Roadster put Tesla on the map, the Model 3 really feels like the car that will bring electric vehicles as a whole into the mainstream. And for Stewart, This car feels like an automotive tipping point, a sign that electric vehicles and hopefully, the infrastructure that supports themhave finallycome into their own.

Follow this link:

Reviewers of Tesla's Newest Vehicle Are Unanimous: The Model 3 Has No Competition - Futurism

Facebook’s Language-Creating AI Bots Are Now Required to Negotiate in English – Futurism

In BriefAfter Facebook researchers discovered their artificiallyintelligent chatbots created a new language to more efficientlynegotiate, they decided to tweak the systems to require that theyuse English. This raises the question of whether the "new language"should be allowed it it means the systems would be better equippedto meet their goals. A Secret Language

While developing negotiating chatbot agents, researchers at theFacebook Artificial Intelligence Research (FAIR)lab noticedback in Junethat the artificially intelligent (AI) bots had spontaneously developed their own non-human language.

In a reportexplaining their research, they noted that this development spawned from the systems goal of improving their negotiation strategies the system of code words they started to use were clearly designed to maximize the efficiency of their communication.

Although the bots started out speaking English, the researchers realized they failed to provide a reward for speaking English. In other words, the systems had no reason to stick to English as it didnt contribute to their end goal of becoming more efficient negotiators.In fact, the systems had multiple incentives to veer away from the language, the same way communities of humans with expertise or niche knowledge create and use shorthand to discuss complex ideas more quickly or efficiently.

In that sense, the behavior should have been predictable. It was, in some sense, a very human adaptation as it was designed to enhance performance and minimize effort something the human brain excels at.

As they explained in their June post, the researchers could decode the new language with fairly little trouble as it was still English-based, but they could never be certain that their translations were 100 percent correct.Its important to remember, there arent bilingual speakers of AI and human languages, FAIRs Dhruv Batra told Fast Code Design.This new language also didnt serve the purpose of the research. Our interest was having bots who could talk to people, explained Mike Lewis, a research scientist at FAIR.

In the end, the researchers decided to tweak the agentsto avoid this drifting away from English.

The initial spontaneous development of the independent language highlights how much we still dont understandabout AIs, which is a huge part of the debate regarding AI research. AI could undoubtedly help us, and very few dispute that the technology is here to stay. However, the way we prepare for a world shared with AI, and whether or not that world will be safe for humans, is hotly debated.

To be sure, much AI-related fear is based more in science-fiction than fact. According Nigel Shadbolt, Oxford professor of artificial intelligence and chairman of the Open Data Institute, We most certainly need to consider the restraints and safeguards that we need to engineer into the hardware, software, and deployment policies of our current AI systems. But the next self-aware computer you encounter will only be appearing at a cinema near you.

The language issue cropping up at FAIR and elsewhere appears to fall squarely within the realm of restraints and safeguards. Should we allow AIs to develop task-specific dialectsif they improve performance, knowing it would mean we couldnt truly understand what they were saying?

Many experts urge that we err on the side of caution. Georgia Tech AI researcher Mark Riedl told Future of Life that AIs trained to optimize rewards could eventually come to see humans as a threat to their optimization plans.

Perhaps the most vocal warnings about AI advancing too quickly have come from Elon Musk and Stephen Hawking. One of the most salient points in their arguments is that by the time we perceive a risk, it may be too late. That may be the best argument of all for shutting down the chatter in a project like this.

See the article here:

Facebook's Language-Creating AI Bots Are Now Required to Negotiate in English - Futurism

Hypothalamic Stem Cells Could Provide New Insights Into Aging – Futurism

Hypothalamic Stem Cells

The hypothalamus is the region of the brain that helps to regulate internal conditions like body temperature and blood concentration, but new research shows that it may fail us as we age. The research indicates that as the hypothalamuss stem cells die off, the region actually starts to promote aging, causing mental and physical faculties to decline at a more rapid pace.

In the past, researchers have observed that the hypothalamus becomes inflamed over time. This lead them to posit that the area is connected to aging. Recent research on mice proved that reversing the inflammation in the hypothalamus increases the animals life span and slows physical deterioration. In this latest study, scientists focusedon the stem cells of the hypothalamus. In younger animals, these stem cells divide and replace damaged and dead cells. However, as this research shows, over time the number of stem cells present in the hypothalamus drops. Inold age, they are essentially gone.

The team believed they were on to something, but undertook some practical experiments to see if their ideas were borne out by the evidence. First, they altered mice genetically to ensure theyd be out of stem cells(at a point earlier than would occur naturally). Reducing the stem cells in the mice by around 70 percent meant a life span that was about 8 percent shorter. This accelerated loss of stem cells also caused a loss of coordination, endurance, and memory, as well as behavior that was less youthful, curious, and social. When the team injected stem cells into the hypothalami of middle-aged mice, those mice gained about about 10 percent more mental and physical capabilities compared to mice injected with regular brain cells.

Originally, scientists believed that the stem cell loss could besignificant because it meant the host was unable to repair and replace damaged and dead cells. However, when the hypothalami of middle-aged mice were injected with stem cells, they improved too rapidly for this to be thecorrect mechanism. Instead, the team suspected microRNAs might be at work.

The RNA molecules, called microRNAs, are manufactured and released by stem cells to carry messages to other cells. Practically, based on the messages they carry, microRNAs mayalter the proteins cells produce. The researchers discovered that the stem cells in the hypothalamus produce massive amounts of microRNAs contained in tiny exosomes. In fact, when they injected mice with exosomes packed with microRNA from young hypothalamus stem cells, the effects were almost as effective in slowing signs of mental and physical aging as injections of stem cells were.

Recent research has focused on the role of mitochondria in aging and on the use of induced pluripotent stem (iPS) cells in combatting aging in hematopoietic stem cells. Research from this year has also shown that cannabis-based treatment appears to reverse aging in the brains of mice. Concerning thisresearch, protecting or replacing the stem cells of the hypothalamus or somehow reinforcing or replacing the microRNA effects could slow aging in humans. This could mean testing current drugs such as acarbose (presently used to treat diabetes) to see if they can suppress the hypothalamic inflammation that causes the stem cells to die.

See the original post:

Hypothalamic Stem Cells Could Provide New Insights Into Aging - Futurism